Citations to this article


In broad terms, there are 3 types of cardiac hypertrophy: normal growth, growth induced by physical conditioning (i.e., physiologic hypertrophy), and growth induced by pathologic stimuli. Recent evidence suggests that normal and exercise-induced cardiac growth are regulated in large part by the growth hormone/IGF axis via signaling through the PI3K/Akt pathway. In contrast, pathological or reactive cardiac growth is triggered by autocrine and paracrine neurohormonal factors released during biomechanical stress that signal through the Gq/phospholipase C pathway, leading to an increase in cytosolic calcium and activation of PKC. Here we review recent developments in the area of these cardiotrophic kinases, highlighting the utility of animal models that are helping to identify molecular targets in the human condition.


Gerald W. Dorn II, Thomas Force


Total citations by year in Crossref

Year: 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Total
Citations: 4 10 5 2 7 13 14 15 16 16 7 109
Citation information

Citations to this article in Crossref (109)

Title and authors Publication Year
Regulation of Phosphatidylinositol-specific Phospholipase C at the Nuclear Envelope in Cardiac Myocytes:
AV Smrcka
Journal of Cardiovascular Pharmacology 2015
Protection of Luteolin-7-O-Glucoside Against Doxorubicin-Induced Injury Through PTEN/Akt and ERK Pathway in H9c2 Cells
H Yao, Z Shang, P Wang, S Li, Q Zhang, H Tian, D Ren, X Han
Cardiovascular Toxicology 2015
Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle
A der Laarse, CM Cobbaert, S Umar
Pulmonary circulation 2015
Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
YK Tham, BC Bernardo, JY Ooi, KL Weeks, JR McMullen
Archives of Toxicology 2015
Atrial Remodeling and Atrial Fibrillation
S Nattel, M Harada
Journal of the American College of Cardiology 2014
Role of copper in regression of cardiac hypertrophy
L Zheng, P Han, J Liu, R Li, W Yin, T Wang, W Zhang, YJ Kang
Pharmacology & Therapeutics 2014
Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy
C Moc, AE Taylor, GP Chesini, CM Zambrano, MS Barlow, X Zhang, AB Gustafsson, NH Purcell
Cardiovascular Research 2014
Regulator of G Protein Signaling 3 Protects Against Cardiac Hypertrophy in Mice: RGS3 R EGULATES CARDIAC HYPERTROPHY
Y Liu, H Huang, Y Zhang, XY Zhu, R Zhang, LH Guan, Q Tang, H Jiang, C Huang
Journal of Cellular Biochemistry 2014
Midkine exacerbates pressure overload-induced cardiac remodeling
S Netsu, T Shishido, T Kitahara, Y Honda, A Funayama, T Narumi, S Kadowaki, H Takahashi, T Miyamoto, T Arimoto, S Nishiyama, T Watanabe, CH Woo, Y Takeishi, I Kubota
Biochemical and Biophysical Research Communications 2014
Post-Genomic Cardiology
J Marín-García
Post-Genomic Cardiology 2014
Gαq signalling: The new and the old
G Sánchez-Fernández, S Cabezudo, C García-Hoz, C Benincá, AM Aragay, F Mayor, C Ribas
Cellular Signalling 2014
The eIF2B-interacting domain of RGS2 protects against GPCR agonist-induced hypertrophy in neonatal rat cardiomyocytes
P Chidiac, AJ Sobiesiak, KN Lee, R Gros, CH Nguyen
Cellular Signalling 2014
Current Topics in Developmental Biology
LR Fiedler, E Maifoshie, MD Schneider
Current topics in developmental biology 2014
MAFbx/Atrogin-1 is required for atrophic remodeling of the unloaded heart
KK Baskin, MR Rodriguez, S Kansara, W Chen, S Carranza, OH Frazier, DJ Glass, H Taegtmeyer
Journal of Molecular and Cellular Cardiology 2014
Protein kinase C inhibitors: a patent review (2010 – present)
ME Sobhia, BK Grewal, ML Paul, J Patel, A Kaur, T Haokip, A Kokkula
Expert Opinion on Therapeutic Patents 2013
Roles of transient receptor potential canonical (TRPC) channels and reverse-mode Na+/Ca2+ exchanger on cell proliferation in human cardiac fibroblasts: Effects of transforming growth factor β1
K Ikeda, T Nakajima, Y Yamamoto, N Takano, T Tanaka, H Kikuchi, G Oguri, T Morita, F Nakamura, I Komuro
Cell Calcium 2013
Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes
CM Sag, S Wagner, LS Maier
Free radical biology & medicine 2013
Key role of ERK1/2 molecular scaffolds in heart pathology
G Tarone, M Sbroggiò, M Brancaccio
Cellular and Molecular Life Sciences 2013
Growth Hormone Replacement Therapy Prevents Sarcopenia by a Dual Mechanism: Improvement of Protein Balance and of Antioxidant Defenses
T Brioche, RA Kireev, S Cuesta, A Gratas-Delamarche, JA Tresguerres, MC Gomez-Cabrera, J Vina
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2013
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
BM Patel, AA Mehta
European Journal of Pharmacology 2012
Epac in cardiac calcium signaling
G Ruiz-Hurtado, E Morel, A Domínguez-Rodríguez, A Llach, F Lezoualc'h, JP Benitah, AM Gomez
Journal of Molecular and Cellular Cardiology 2012
Transcription coactivator Eya2 is a critical regulator of physiological hypertrophy
SH Lee, J Kim, JY Ryu, S Lee, DK Yang, D Jeong, J Kim, SH Lee, JM Kim, RJ Hajjar, WJ Park
Journal of Molecular and Cellular Cardiology 2011
Expression patterns of imprinted gene Inpp5f-v3 during mouse brain development
C Yan, H Hongjuan, X Yanjiang, H Zhengbin, L Kai, Z Fengwei, H Jing, W Qiong
Journal Of Molecular Histology 2011
Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling-
JJ Leenders, YM Pinto, EE Creemers
Journal of Molecular and Cellular Cardiology 2011
Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy
ED Frohlich, A González, J Díez
Journal of Hypertension 2011